• Belzutifan active in von Hippel-Lindau disease-associated renal cell carcinoma

    6 days ago - By Healio

    Belzutifan demonstrated clinical efficacy among patients with von Hippel-Lindau disease-associated renal cell carcinoma, according to results of a phase 2 study published in The New England Journal of Medicine.
    Belzutifan , a novel small-molecule inhibitor of hypoxia-inducible factor-2 alpha, became the first FDA-approved treatment for von Hippel-Lindau disease in August, based on results of the ongoing, open-label Study 004.
    “Based on the results of this study and the subsequent FDA approval of belzutifan, we now have, for the first time, a systemic treatment option for
    Read more ...